# US 2019/0054167 A1 · Method for treating rheumatoid arthritis with a human il-6 receptor antibody and methotrexate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0054167 A1
- Document ID: US20190054167A1
- Status: Published application
- Kind: A1
- Application number: 15/919,429
- Filed: 2018-03-13
- Published: 2019-02-21
- Earliest claimed: 2003-04-28
- Assignees: Chugai Seiyaku Kabushiki Kaisha
- Applicants: Chugai Seiyaku Kabushiki Kaisha
- Inventors: Osamu Okuda; Noriaki Yoshida; Ravinder Nath Maini
- Web page: https://patentgrep.com/patent/US20190054167A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method for treating rheumatoid arthritis in a patient, comprising administering to a patient a combination of (i) 4 mg/kg or 8 mg/kg of a humanized anti-interleukin-6 receptor (anti-IL-6R) antibody MRA every four weeks and (ii) methotrexate (MTX).

### Claim 17 (depends on 16)

The method of claim 16, wherein the anti-IL-6R monoclonal antibody MRA is administered at a dose of 4 mg/kg.

### Claim 18 (depends on 16)

The method of claim 16, wherein the anti-IL-6R monoclonal antibody MRA is administered at a dose of 8 mg/kg.

### Claim 19 (depends on 16)

The method of claim 16, wherein the patient is administered a 4 mg/kg dosage at the first dose and increased to an 8 mg/kg dosage at a later dose.

### Claim 20 (depends on 16, 19)

The method of claim 16 or 19, wherein the MTX is administered once per week.

### Claim 21 (depends on 20)

The method of claim 20, wherein the MTX is administered orally.

### Claim 22 (depends on 20)

The method of claim 20, wherein the MTX is administered at a dose in a range of 10 to 25 mg.

### Claim 23 (depends on 20)

The method of claim 20, wherein the anti-IL-6R monoclonal antibody MRA is administered intravenously.

### Claim 24 (depends on 16)

The method of claim 16, wherein the patient achieves an improved American College of Rheumatology (ACR) response in the patient of ACR20, ACR50 or ACR70 compared to administering the anti-IL-6R antibody MRA or MTX alone.

### Claim 25 (depends on 16)

The method of claim 16, wherein the patient was prior treated with MTX.

### Claim 26 (depends on 25)

The method of claim 25, wherein the patient previously had an inadequate response to MTX.

### Claim 27

A method for treating rheumatoid arthritis in a patient, comprising administering to a patient a combination of (i) 4 mg/kg or 8 mg/kg of a humanized anti-interleukin-6 receptor (anti-IL-6R) antibody humanized PM-1 (hPM-1) every four weeks and (ii) methotrexate (MTX).

### Claim 28 (depends on 27)

The method of claim 27, wherein the anti-IL-6R monoclonal antibody hPM-1 is administered at a dose of 4 mg/kg.

### Claim 29 (depends on 27)

The method of claim 27, wherein the anti-IL-6R monoclonal antibody hPM-1 is administered at a dose of 8 mg/kg.

### Claim 30 (depends on 27)

The method of claim 27, wherein the patient is administered a 4 mg/kg dosage at the first dose and increased to an 8 mg/kg dosage at a later dose.

### Claim 31 (depends on 27, 30)

The method of claim 27 or 30, wherein the MTX is administered once per week.

### Claim 32 (depends on 31)

The method of claim 31, wherein the MTX is administered orally.

### Claim 33 (depends on 31)

The method of claim 31, wherein the MTX is administered at a dose in a range of 10 to 25 mg.

### Claim 34 (depends on 31)

The method of claim 31, wherein the anti-IL-6R monoclonal antibody hPM-1 is administered intravenously.

### Claim 35 (depends on 27)

The method of claim 27, wherein the patient achieves an improved American College of Rheumatology (ACR) response in the patient of ACR20, ACR50 or ACR70 compared to administering the anti-IL-6R antibody hPM-1 or MTX alone.

### Claim 36 (depends on 27)

The method of claim 27, wherein the patient was prior treated with MTX.

### Claim 37 (depends on 36)

The method of claim 36, wherein the patient previously had an inadequate response to MTX.
